- Home
- ONDS vs INBX Comparison
ONDS vs INBX Comparison
Compare ONDS & INBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ONDS
- INBX
- Stock Information
- Founded
- ONDS 2014
- INBX 2010
- Country
- ONDS United States
- INBX United States
- Employees
- ONDS N/A
- INBX N/A
- Industry
- ONDS Telecommunications Equipment
- INBX Biotechnology: Pharmaceutical Preparations
- Sector
- ONDS Telecommunications
- INBX Health Care
- Exchange
- ONDS Nasdaq
- INBX Nasdaq
- Market Cap
- ONDS 218.8M
- INBX 218.9M
- IPO Year
- ONDS N/A
- INBX 2020
- Fundamental
- Price
- ONDS $2.07
- INBX $13.49
- Analyst Decision
- ONDS Buy
- INBX Hold
- Analyst Count
- ONDS 1
- INBX 1
- Target Price
- ONDS $4.00
- INBX N/A
- AVG Volume (30 Days)
- ONDS 11.0M
- INBX 84.0K
- Earning Date
- ONDS 11-12-2024
- INBX 11-14-2024
- Dividend Yield
- ONDS N/A
- INBX N/A
- EPS Growth
- ONDS N/A
- INBX N/A
- EPS
- ONDS N/A
- INBX 119.38
- Revenue
- ONDS $8,024,937.00
- INBX $1,568,000.00
- Revenue This Year
- ONDS N/A
- INBX N/A
- Revenue Next Year
- ONDS $279.95
- INBX N/A
- P/E Ratio
- ONDS N/A
- INBX $0.11
- Revenue Growth
- ONDS N/A
- INBX 19.24
- 52 Week Low
- ONDS $0.54
- INBX $10.80
- 52 Week High
- ONDS $3.40
- INBX $18.95
- Technical
- Relative Strength Index (RSI)
- ONDS 52.50
- INBX 40.15
- Support Level
- ONDS $1.82
- INBX $12.51
- Resistance Level
- ONDS $2.27
- INBX $14.86
- Average True Range (ATR)
- ONDS 0.42
- INBX 1.03
- MACD
- ONDS -0.10
- INBX -0.20
- Stochastic Oscillator
- ONDS 15.82
- INBX 22.69
About ONDS Ondas Holdings Inc.
Ondas Holdings Inc designs, develops, manufactures, sells, and supports FullMAX Software Defined Radio (SDR) technology in the United States, Israel, and India. The company operates in two business segments namely Ondas Networks and Ondas Autonomous Systems. The company generates maximum revenue from Ondas Autonomous Systems through the sales of the Optimus system and separately priced support, maintenance, and ancillary services related to the sale of the Optimus system.
About INBX Inhibrx Inc.
Inhibrx Biosciences Inc is a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using its proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize their multivalent formats where the precise valency can be optimized in a target-centric way to mediate what experts consider to be the predominant agonist function.